Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GERN heads into the final stretch before its November 5 earnings report with short sellers maintaining elevated positions and the stock down 24% in a month, trading at $1.20.
Short interest is the defining tension here. Bears hold 12.5% of the free float short, a level ORTEX classifies as high, and the position has grown 4.6% over the past month. The pace of that build is notable: shorts climbed above 90 million shares briefly in mid-September before pulling back to around 80 million, where they have stabilised. The FINRA fortnightly settlement count puts the official figure at 82.6 million shares, with days-to-cover at 6.7, meaning at current volumes it would take shorts more than a week to exit. That alone frames this as a crowded position. Yet the borrow market is not confirming stress: cost to borrow is just 0.51%, essentially free money to maintain a short, and availability is loose at 547%, meaning there are more than five shares available to borrow for every one already lent out. Availability has been widening over recent weeks, back toward the high end of the 12-month range. The options market adds little drama. The put/call ratio is 0.28, fractionally below its 20-day mean of 0.29 and well within one standard deviation of normal. Call volume continues to outpace puts by roughly three to one, which is the structural norm for this name rather than a fresh bullish signal.
The Street is divided but the bears are better credentialled. All analyst data here predates the standard 14-day window for fresh attribution, but the direction of travel from the most recent actions tells a clear story. Goldman Sachs reinstated coverage with a Sell rating and a $1.00 target in July 2025. Scotiabank downgraded in May 2025 to Sector Perform with a $1.50 target. The bulls, led by Needham and Barclays (both maintaining Buy/Overweight with $4.00 targets), argue the EU approval of Rytelo for low-risk myelodysplastic syndrome opens a revenue stream from 2026, and that imetelstat's disease-modification profile gives it a durable commercial moat. The bears point to flat revenues, the IMpactMF trial delay into the second half of 2026, and a pipeline of clinical, competitive and IP risks. At $1.20, the mean analyst target of $4.00 implies substantial upside on paper, but with Goldman carrying a $1.00 target the consensus average masks a wide dispersion. Factor scores tell their own story: EPS momentum ranks in the 96th percentile over 30 days and the 79th over 90 days, with EPS surprise in the 93rd percentile. But the short score rank sits in the bottom quintile at 20, reflecting the persistently elevated short interest, and the dividend score of 32 is irrelevant for a cash-burning biotech.
Institutional ownership offers a more constructive undercurrent. BlackRock added 1.8 million shares in the quarter ending September 30, bringing its stake to 7.6% of shares outstanding. State Street, which filed a fresh Schedule 13G in August disclosing a 5.6% position, added 5.4 million shares in the same period. Soleus Capital's stake climbed from 5.2% to 6.5% as of its May filing. RA Capital, the largest disclosed 5%-plus holder at 9.9%, held steady. None of these are activist 13D filings: all are passive 13G holders, so there is no activist agenda on the register. The caveat applies: stakes are as last disclosed around the 5% threshold and a holder dropping below that level need not file again.
Insider activity adds little colour. Director Robert Spiegel received quarterly stock awards in September worth roughly $7,800, a compensation mechanic rather than a discretionary signal. The most recent open-market purchase of note was Chief Commercial Officer James Ziegler's $160,000 buy at $1.60 in February 2025, when the stock was trading higher than it is today.
Earnings history suggests the market can move sharply on results. The August 2026 print triggered a 9.2% one-day decline. A separate event in early August 2026 drew a 17.2% one-day gain. The range of those reactions, roughly 9% to 17%, frames how much event risk the November 5 report carries at a $1.20 entry price.
The alt data available for GERN covers Medicaid drug utilisation from CMS through Q1 2026 and active clinical trial status from the National Library of Medicine, but neither dataset has been measured or tested as a lead against Geron's reported figures, so neither can be treated as forward-pointing. They are background colour only.
With 28 days to the next report, the question is whether the loose borrow market and slowly growing short position resolves before or after the November catalyst.
See the live data behind this article on ORTEX.
Open GERN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
